Adaptimmune Therapeutics CEO James Noble's 2019 pay rises 7% to $2.8M
Adaptimmune Therapeutics reports 2019 executive compensation
By ExecPay News
Published: April 20, 2020
Adaptimmune Therapeutics reported fiscal year 2019 executive compensation information on April 20, 2020.
In 2019, five executives at Adaptimmune Therapeutics received on average a compensation package of $1.7M, a 6% decrease compared to previous year.
Average pay of disclosed executives at Adaptimmune Therapeutics
James Noble, Chief Executive Officer, received $2.8M in total, which increased by 7% compared to 2018. 68% of Noble's compensation, or $1.9M, was in option awards. Noble also received $255K in non-equity incentive plan, $606K in salary, as well as $43K in other compensation.
Adrian Rawcliffe, Chief Executive Officer, received a compensation package of $2.1M, which increased by 52% compared to previous year. 66% of the compensation package, or $1.4M, was in option awards.
William Bertrand, Chief Operating Officer, earned $1.4M in 2019, a 6% increase compared to previous year.
Helen Tayton-Martin, Chief Business Officer, received $1.4M in 2019, which increases by 6% compared to 2018.
John Lunger, Chief Operating Officer, earned $933K in 2019.
Related executives
Adrian Rawcliffe
Adaptimmune Therapeutics
Chief Executive Officer
James Noble
Adaptimmune Therapeutics
Chief Executive Officer
William Bertrand
Adaptimmune Therapeutics
Chief Operating Officer
Helen Tayton-Martin
Adaptimmune Therapeutics
Chief Business Officer
John Lunger
Adaptimmune Therapeutics
Chief Operating Officer
You may also like
Source: SEC filing on April 20, 2020.